10-K: Xencor Reports 2025 Financials, Advances Clinical Pipeline

Xencor, a clinical-stage biopharmaceutical company, reported a net loss of $91.9 million in 2025, driven by increased R&D, while advancing multiple oncology and autoimmune drug candidates and remediating prior material weaknesses in internal controls.

Summary

• Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases.
• The company reported a net loss of $91.9 million for the year ended December 31, 2025, a significant reduction from $232.6 million in 2024.
• Total revenue increased by $15.1 million to $125.6 million in 2025, primarily driven by royalty revenue from Alexion and milestone payments from Incyte.
• Research and development (R&D) expenses increased by $11.7 million to $239.4 million in 2025, reflecting the advancement of clinical programs.
• Cash, cash equivalents, and marketable debt securities totaled $610.8 million as of December 31, 2025, down from $706.7 million in 2024.
• The company advanced several wholly-owned clinical candidates, including XmAb819 (clear cell renal cell carcinoma), XmAb541 (gynecologic and germ cell tumors), XmAb942 (ulcerative colitis), plamotamab (rheumatoid arthritis), and XmAb657 (idiopathic inflammatory myopathies).
• Further development of vudalimab was paused, and expansion cohorts of XmAb808 in combination with pembrolizumab were not initiated.
• Material weaknesses in internal control over financial reporting, previously disclosed, were fully remediated as of December 31, 2025.
• Xencor is currently involved in patent infringement litigation with Merus N.V. regarding its bispecific antibody product candidates.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting significant progress in the clinical pipeline, a substantial reduction in net loss, and successful remediation of internal control issues, despite ongoing R&D expenses and litigation risks.

Positives

• Net loss significantly reduced to $91.9 million in 2025 from $232.6 million in 2024.
• Total revenue increased by $15.1 million to $125.6 million in 2025.
• Alexion royalty revenue increased to $70.1 million in 2025 from $58.2 million in 2024.
• Incyte milestone payments totaled $41.5 million in 2025, including $12.5 million for sBLA acceptance, $25.0 million for approval, and $4.0 million for Phase 2 dosing.
• Amgen initiated a Phase 3 XALience study for xaluritamig in metastatic castration-resistant prostate cancer (mCRPC), triggering a $30.0 million milestone payment.
• Zenas announced positive results from the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis, meeting the primary endpoint.
• Zenas announced positive results from the Phase 3 INDIGO trial of obexelimab in immunoglobulin G4-related disease (IgG4-RD), meeting the primary endpoint.
• XmAb819 demonstrated evidence of anti-tumor activity and an acceptable safety profile in a Phase 1 ccRCC study, with 25% partial response rate and 70% disease control rate in the target dose range.
• XmAb541 showed confirmed partial responses in three patients in an early efficacy cohort of its Phase 1 gynecologic and germ cell tumor study.
• XmAb942 was well tolerated in a Phase 1 healthy volunteer study, with an estimated human half-life greater than 71 days, supporting a 12-week dosing interval.
• Plamotamab's Phase 1 study in hematologic cancers showed favorable tolerability and comparable preliminary efficacy data to a competitor molecule.
• XmAb657 demonstrated deep B-cell depletion (>99.98%) in non-human primate studies, sustained for at least 42 days, with good preclinical tolerability.
• Material weaknesses in internal control over financial reporting were fully remediated as of December 31, 2025.
• A patent term extension related to the Xtend Fc domain for antibodies targeting C5 (Ultomiris) was announced, extending the expected royalty term into December 2028 in the United States.

Negatives

• The company has incurred significant losses since its inception, with an accumulated deficit of $796.0 million as of December 31, 2025.
• Research and development expenses increased by $11.7 million to $239.4 million in 2025.
• Cash, cash equivalents, and marketable debt securities decreased to $610.8 million as of December 31, 2025, from $706.7 million in 2024.
• Further development of vudalimab, a PD-1 x CTLA-4 bispecific antibody, was paused.
• The company decided not to initiate expansion cohorts of XmAb808 in combination with pembrolizumab.
• Janssen terminated its rights to plamotamab in June 2024, although Xencor is now developing it internally for autoimmune diseases.
• Asset impairment charges of $9.2 million were recognized in 2025 related to the decision to pause development of certain programs.
• The company is involved in ongoing patent infringement litigation with Merus N.V., which could result in substantial costs and potential liability.
• The current Shelf Registration Statement for the ATM Offering will expire on February 27, 2026, requiring a new filing.

Risks

• Success depends on the ability to use and expand the XmAb technology platform to build a pipeline and develop marketable products; there is no certainty candidates will receive regulatory approval or be successfully commercialized.
• The clinical development stage of operations may make it difficult to evaluate business success to date and assess future viability.
• Preliminary, interim, and topline data from clinical trials may change as more patient data become available, potentially resulting in material changes in the final data.
• Business and results of operations could be adversely impacted by inflation.
• The company has incurred significant losses since inception and anticipates continued significant losses for the foreseeable future; it may never be profitable.
• Additional financing will be required, and the company may be unable to raise sufficient capital, which could lead to delays, reductions, or abandonment of research and development programs or commercialization efforts.
• The market price of the common stock is likely to be highly volatile, and investors could lose all or part of their investment.
• Principal stockholders, directors, and management own a significant percentage of the stock and will be able to exert significant control over matters subject to stockholder approval.
• Raising additional funds through debt or equity financing may be dilutive, and raising funds through licensing may require relinquishing rights to technology or product candidates.
• Future sales and issuances of common stock or rights to purchase common stock, including pursuant to equity incentive plans, could result in additional dilution of percentage ownership and cause the stock price to fall.
• If material weaknesses in internal control over financial reporting are identified in the future or if an effective system is not maintained, the company may not be able to accurately or timely report financial condition or results of operations, leading to a decline in stock price.
• Inability to obtain, maintain, and enforce intellectual property protection covering products and future products could adversely affect the ability to compete in the market.
• Reliance on in-licensed intellectual property; failure to comply with obligations under these arrangements could lead to loss of rights or damages.
• The company may be required to reduce the scope of its intellectual property due to third-party intellectual property claims.
• Others may allege that products infringe their patents and other property rights, which may result in costly litigation and, if unsuccessful, could cause substantial damages or limit the ability to commercialize products.
• Inability to prevent disclosure of trade secrets and other proprietary information could significantly diminish the value of technology and products.
• Failure to obtain patent term extension and data exclusivity for any therapeutic candidates could materially harm the business.
• Reliance on third-party manufacturers; problems or loss of drug material during production or non-compliance could delay or stop product development.
• Existing and future partnerships are important; inability to maintain or unsuccessful partnerships could adversely affect the business.
• Reliance upon third-party contractors and service providers for most aspects of development programs; failure to provide suitable quality or timely services may cause delay or failure.
• Clinical trials are expensive, take years to conduct, and their outcome is uncertain; results of earlier studies may not be predictive of future trial results, and trials may fail to prove product candidates are safe and effective.
• Adverse side effects or other safety risks associated with product candidates could delay or preclude approval, cause suspension or discontinuation of clinical trials, and abandonment of product candidates.
• Delays or difficulties in the enrollment of patients in clinical trials could delay or prevent receipt of necessary regulatory approvals.
• The industry is subject to competition for skilled personnel, and challenges to identify and retain key personnel could impair the ability to effectively conduct and grow operations.
• The development and commercialization of biologic products are subject to extensive regulation, and the company may not obtain regulatory approvals for any of its product candidates.
• Significant competition from other biotechnology and pharmaceutical companies; operating results will suffer if the company fails to compete effectively.
• Present and future legislation may increase the difficulty and cost for obtaining marketing approval and commercializing product candidates and affect the prices obtainable.
• Business involves the controlled use of hazardous materials, subject to environmental and occupational safety laws; continued compliance may incur substantial costs, and failure to maintain compliance could result in liability.
• The company may become subject to the risk of product liability claims.
• Disruptions at the FDA, SEC, and other government agencies caused by changing priorities or funding shortages could hinder their ability to function, preventing new or modified products from being developed, reviewed, approved, or commercialized in a timely manner.
• The company may be subject to damages resulting from claims that it or its employees have wrongfully used or disclosed alleged trade secrets of former employers.
• Business could be negatively impacted by cybersecurity threats and other disruptions, including the theft of intellectual property, compromising information and exposing the company to liability.
• Unfavorable global economic or political conditions could adversely affect business, financial condition, or results of operations.
• The increasing use of social media platforms presents new risks and challenges.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities or inhibit the ability to collect and process data globally.
• The company may be vulnerable to disruption, damage, and financial obligation as a result of system failures.
• Employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

Future Outlook

Xencor anticipates initiating first-in-human studies for XmAb412 during 2026 and expects its existing financial resources to fund operations through at least 2028. Incyte plans to file a supplemental Biologics License Application for Monjuvi as a first-line treatment for newly diagnosed DLBCL in the first half of 2026, and Zenas expects to submit a BLA for obexelimab for IgG4-RD to the FDA in Q2 2026 and an MAA to the EMA in H2 2026.

Management Comments

• "We believe our preclinical and clinical data to date, together with our established partnerships, has validated our platform to a degree, most of the programs are in early stages of development."
• "We believe our existing cash, cash equivalents and marketable securities, together with interest thereon and expected milestones and royalty payments will be sufficient to fund our operations through 2028."
• "Management believes that the material weaknesses previously disclosed in prior periods have been fully remediated."

Industry Context

StockSavvy.ai notes that Xencor operates in a highly competitive biopharmaceutical landscape, particularly in oncology and autoimmune diseases, where numerous large pharmaceutical and biotechnology companies are developing competing bispecific antibody platforms and other advanced therapies. The company's strategy of advancing a broad portfolio of wholly-owned candidates while leveraging partnerships for development and commercialization aligns with industry trends seeking to de-risk R&D and maximize asset value. The positive clinical updates for several pipeline candidates, including XmAb819, XmAb541, XmAb942, plamotamab, and XmAb657, demonstrate progress in a challenging development environment. The significant reduction in net loss for 2025, coupled with increased revenue from collaborations, indicates effective portfolio management and the value of its XmAb technology, even as R&D expenses continue to rise in line with industry-standard development costs for clinical-stage assets.

Comparison to Industry Standards

• Xencor's XmAb 2+1 bispecific antibody format for solid tumors, exemplified by XmAb819 and XmAb541, aims to achieve selective engagement and killing of cells with high target expression, potentially offering improved tolerability compared to conventional monovalent targeting, a key challenge in solid tumor oncology.
• The estimated human half-life of XmAb942 (anti-TL1A) of greater than 71 days supports a 12-week dosing interval, which is competitive with or superior to the dosing frequency of some existing or developing therapies for inflammatory bowel diseases, potentially reducing patient burden.
• Plamotamab's preliminary efficacy and favorable tolerability in hematologic cancers, when cross-compared to a competitor molecule within the class, suggests it could be a competitive B-cell targeted T-cell engager for autoimmune diseases like rheumatoid arthritis.
• The deep B-cell depletion (>99.98%) and sustained effect for at least 42 days observed with XmAb657 in non-human primates indicates a potentially durable therapeutic effect, which is a desirable characteristic for treatments in idiopathic inflammatory myopathies, an area with substantial unmet medical need.
• The global market for therapies to treat Crohn's disease and ulcerative colitis is projected to reach approximately $40 billion by 2032, and the global market for rheumatoid arthritis therapies is projected to reach approximately $30 billion by 2030, indicating substantial market opportunities for Xencor's autoimmune pipeline if successful.

Corporate Governance

Legal Proceedings

• Ongoing patent infringement litigation initiated by Merus N.V. in the United States District Court of the District of Delaware on August 5, 2024. Merus alleges that Xencor's manufacture, use, offer for sale, sale, and/or importation of common light chain antibodies and heterodimeric antibodies (including plamotamab, vudalimab, and XmAb819) infringes certain claims of Merus patents (U.S. Patent Nos. 9,944,695, 9,358,286, 11,926,859, and 12,123,043).
• Xencor filed a motion to dismiss the initial Merus complaint on October 10, 2024, arguing that all accused activities are covered by the 35 U.S.C. § 271(e)(1) safe harbor. The Court granted this motion on September 30, 2025, but permitted Merus to file an amended complaint.
• Merus filed a first amended complaint on November 11, 2025, and Xencor filed a motion to dismiss this amended complaint on December 16, 2025. A hearing on this motion was held on February 17, 2026.
• Xencor filed for inter partes review of Merus U.S. Patent Nos. 9,358,286 and 11,926,859 before the U.S. Patent and Trademark Appeal Board (PTAB) on February 11, 2025. The PTAB granted institution of this review on September 26, 2025, with oral argument scheduled for June 24, 2026.
• Xencor believes it has strong defenses to Merus's claims, including defenses of invalidity and/or non-infringement, some of which have been accepted by the district court and preliminarily by the PTAB.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity financings (ATM Offering, new shelf registration), volatility in stock price due to clinical trial results, regulatory decisions, competition, and intellectual property disputes. Principal stockholders, directors, and management exert significant control.
• Employees: The company's ability to attract, retain, and motivate high-quality employees is critical, supported by equity incentives and an Employee Stock Purchase Plan, aligning employee interests with stockholders.
• Patients: The development of engineered antibody therapeutics aims to address unmet medical needs in cancer and autoimmune diseases, potentially offering new treatment options and improved standards of care.
• Partners/Collaborators: The success of partnered programs directly impacts Xencor's milestone and royalty revenues. Termination of agreements or changes in partner priorities can adversely affect Xencor's financial and strategic outlook.
• Creditors: The company has significant liabilities related to the sale of future royalties, which are accounted for as debt, impacting its financial leverage and future cash flow obligations.

Next Steps

• Initiate first-in-human studies for XmAb412 during 2026.
• Incyte expects to file a supplemental Biologics License Application (sBLA) for Monjuvi as a first-line treatment for newly diagnosed DLBCL in the first half of 2026.
• Zenas anticipates submitting a Biologics License Application (BLA) for obexelimab for IgG4-RD to the U.S. Food and Drug Administration in the second quarter of 2026.
• Zenas anticipates submitting a Marketing Authorization Application (MAA) for obexelimab for IgG4-RD to the European Medicines Agency in the second half of 2026.
• Oral argument is scheduled for June 24, 2026, for the inter partes review of Merus U.S. Patent Nos. 9,358,286 and 11,926,859.
• File a new shelf registration statement on Form S-3 with the SEC simultaneously with, or promptly after, the filing of this Annual Report on Form 10-K, to replace the expiring one.
• Continue dose-expansion and dose-escalation in clear cell renal cell carcinoma (RCC) for XmAb819, and enroll tumor expansion cohorts in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and papillary renal cell carcinoma (pRCC).
• Continue the Phase 1 dose-escalation study for XmAb541 in advanced gynecologic and germ cell tumors.
• Continue the Phase 2b study of XmAb942 in ulcerative colitis (XENITH-UC).
• Continue the Phase 1b proof-of-concept study of plamotamab in rheumatoid arthritis.
• Continue the Phase 1 study of XmAb657 for idiopathic inflammatory myopathies.

Key Dates

Recommendation

Xencor's 2025 annual report shows a significant reduction in net loss and increased revenue, driven by successful milestone achievements from partnerships and positive early-stage clinical data for several wholly-owned pipeline candidates. The remediation of internal control weaknesses is also a positive. However, the company continues to incur substantial R&D expenses, operates at a net loss, and faces ongoing patent litigation, which introduces uncertainty. While the pipeline shows promise, most programs are in early stages, and future capital raises are anticipated, which could lead to dilution. Given the mix of positive operational progress and inherent risks of a clinical-stage biopharmaceutical company, a 'hold' recommendation is appropriate, suggesting investors monitor pipeline advancements and resolution of legal matters.

Keywords

Biopharmaceutical, Antibody Therapeutics, Oncology, Autoimmune Diseases, XmAb Technology, Clinical Trials, SEC Filing, 10-K, Drug Development, Protein Engineering, Financial Results, Pipeline, Partnerships, Intellectual Property, Regulatory Approval, Xencor